MGMT and glioblastoma: In summary, our study provides compelling evidence that SQ-TMZ NPs offer a significant therapeutic advantage over free TMZ by improving drug stability, enhancing BBB penetration, and overcoming MGMT-mediated resistance in glioblastoma cells.